Prolonged response to trastuzumab in a patient with HER2-nonamplified breast cancer with elevated HER2 dimerization harboring an ERBB2 S310F mutation

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 9, 2015, Pages 1066-1070

  Chumsri, Saranya ^a   Weidler, Jodi ^b,e   Ali, Siraj ^c   Balasubramanian, Sohail ^c   Wallweber, Gerald ^b   De Fazio Eli, Lisa ^b,f   Chenna, Ahmed ^b   Huang, Weidong ^b   De Ridder, Angela ^d   Goicocheal, Lindsay ^d   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

^c FOUNDATION MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e CEPHEID   (United States)

^f N of One   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; EVEROLIMUS; FLUOROURACIL; FULVESTRANT; GEMCITABINE; METHOTREXATE; NAVELBINE; PACLITAXEL; PERTUZUMAB; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ESTRADIOL; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ADJUVANT THERAPY; ADULT; ALLERGIC REACTION; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST CARCINOMA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CAUCASIAN; CHEMOEMBOLIZATION; CHILD PUGH SCORE; DIMERIZATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDERMAL GROWTH FACTOR RECEPTOR 2 NONAMPLIFIED BREAST CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HOSPICE; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION TEST; LEFT LUMPECTOMY; LIVER BIOPSY; LIVER METASTASIS; LONG TERM CARE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUTATION; PARTIAL MASTECTOMY; PRIMARY TUMOR; PROTEIN EXPRESSION; SENTINEL LYMPH NODE BIOPSY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMISTRY; GENETICS; PATHOLOGY; PROTEIN MULTIMERIZATION; RETREATMENT; SECONDARY; SEGMENTAL MASTECTOMY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; ESTRADIOL; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; RECEPTOR, ERBB-2; RETREATMENT; TRASTUZUMAB;

EID: 84941770307     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0132     Document Type: Article

References (28)

1. Patani N, Martin LA, Reis-Filho JS, Dowsett M. The role of caveolin-1 in human breast cancer. Breast Cancer Res Treat 2012;131:1-15.
2. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-5546.
3. Shi Y, Huang W, Tan Y, et al. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol 2009;18:11-21.
4. Larson JS, Goodman LJ, Tan Y, et al. Analytical validation of a highly quantitative, sensitive, accurate, and reproducible assay (HERmark) for the measurement of HER2 total protein and HER2 homodimers in FFPE breast cancer tumor specimens. Patholog Res Int 2010;2010:814176.
5. Huang W, Reinholz M, Weidler J, et al. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am J Clin Pathol 2010;134:303-311.
6. Lipton A, Kostler WJ, Leitzel K, et al. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 2010;116:5168-5178.
7. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-5287.
8. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-2467.
9. Ram TG, Schelling ME, Hosick HL. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification. Cell Growth Differ 2000;11:173-183.
10. Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003;100:8933-8938.
11. Lee-Hoeflich S T, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008;68:5878-5887.
12. Lipton A, Goodman L, Leitzel K, et al. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2013;141:43-53.
13. Mukherjee A, Badal Y, Nguyen XT, et al. Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins. PLoS One 2011;6:e16443.
14. Wallweber J, Chenna A, Ravanera R, et al. Profiling HER3/ErbB3 activation in formalin-fixed, paraffin-embedded (FFPE) breast tumor samples that expresss high and low HER2/ErbB2 levels using proximitybased immunoassays. [abstract]. Cancer Res 2013;73:Abstract 3029.
15. Franklin MC, Carey KD, Vajdos F F, et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-328.
16. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400-404.
17. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-399.
18. Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010;466:869-873.
19. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486:353-360.
20. Cancer Genome Atlas Research Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
21. Lee JW, Soung YH, Seo SH, et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006;12:57-61.
22. Shah S P, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-813.
23. Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012;486:405-409.
24. Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3:224-237.
25. Kancha RK, von Bubnoff N, Bartosch N, et al. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS One 2011;6:e26760.
26. Greulich H, Kaplan B, Mertins P, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A 2012;109:14476-14481.
27. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.
28. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-607.